Sign inJoin waitlistJoin the waitlist

Tracey McLaughlin

Professor-Univ Med Line · Stanford Health Care

Credentials: · · · ·

History

Stanford University
1998–2000
Internal Medicine
Santa Clara Valley Healthcare
1994–1995
Univ of California, San Francisco Sch of Med
1990–1994
Stanford University
1986–1990

Research

B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies
Nature Medicine · 2011 · 858 citations
Use of metabolic markers to identify overweight individuals who are insulin resistant
Annals of Internal Medicine · 2003 · First of 6 authors · 765 citations
Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?
The American Journal of Cardiology · 2005 · First of 8 authors · Corresponding · 504 citations

GR
Gerald Reaven
59 papers
Fahim Abbasi
58 papers · 31 as a fellow
CL
Cindy Lamedola
25 papers
Dalia Perelman
16 papers
JC
James Chu
10 papers · 1 as a fellow
Mimi Young
7 papers
Edgar Engleman
5 papers
Peter Reaven
5 papers
Sun Kim
5 papers · 4 as a resident
AL
Alice Liu
4 papers · 1 as a fellow
John Cooke
4 papers
John Morton
4 papers

Grants

Rapid Gastric Emptying: A Modifiable Risk Factor for Postbariatric Hypoglycemia
National Institute of Diabetes and Digestive and Kidney Diseases · R01
Contact PI · $681.4K · Stanford University
2026–2030
Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention
National Institute of Diabetes and Digestive and Kidney Diseases · R01
Contact PI · $1.4M · Stanford University
2025–2029
Obesity and COVID-19: Role of Adipose Tissue
National Institute of Allergy and Infectious Diseases · R21
Contact PI · $432.9K · Stanford University
2021–2023
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
National Institute of Diabetes and Digestive and Kidney Diseases · R01
Contact PI · $3.2M · Stanford University
2017–2023

Clinical trials

Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention
Principal investigator · Not yet recruiting · Phase 4
Stanford University
2024–2027
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
Principal investigator · Recruiting · Phase 2
Stanford University
2023–2029
Improving Glycemic Control Using a Virtual Weight Control Program and Continuous Glucose Monitoring
Principal investigator · Completed
Pennington Biomedical Research Center
2023–2025
Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2
Principal investigator · Recruiting
Stanford University
2023–2025